Tianjin Development (00882) announced that on November 19, 2025, its indirectly held non-wholly owned subsidiary, Lisheng Pharmaceuticals, entered into the eleventh wealth management agreement with Industrial Bank Co., Ltd. and its wealth management subsidiary. The agreement involves subscribing to a fixed-income investment product with a principal amount of RMB 30 million (approximately HKD 32.82 million).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments